Literature DB >> 2511761

Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.

H W Bruckner1, B T Motwani.   

Abstract

Leuprolide acetate, a gonadotropin-releasing hormone analogue, produced a variety of beneficial therapeutic responses in five patients with ovarian carcinoma. Four patients had failed intensive chemotherapy with alkylating agents, cisplatin, and Adriamycin. All had one or more clinical conditions that precluded treatment with cytotoxic agents and characteristics associated with resistance to hormone therapy. Our findings support evaluation of expanded eligibility criteria for new hormonal therapy in cases of refractory ovarian carcinoma.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2511761     DOI： 10.1016/0002-9378(89)90669-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


  7 in total

1.  Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence.

Authors:  C Liebow; D H Crean; A V Schally; T S Mang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

2.  Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.

Authors:  T Yano; J Pinski; S Radulovic; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

3.  Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  T Yano; J Pinski; G Halmos; K Szepeshazi; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

Review 4.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 5.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 6.  Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).

Authors:  Hongyi Li; Yu Liu; Yang Wang; Xia Zhao; Xiaorong Qi
Journal:  Oncol Rep       Date:  2021-08-26       Impact factor: 3.906

7.  A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

Authors:  M J Lind; B M Cantwell; M J Millward; A Robinson; M Proctor; D Simmons; J Carmichael; A L Harris
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.